FEIBA safety profile in multiple modes of clinical and home-therapy application

Haemophilia : the Official Journal of the World Federation of Hemophilia
H Luu, B M Ewenstein

Abstract

The development of neutralizing antibodies to factor VIII or IX therapeutic concentrates remains the most serious and challenging complication in the management of patients with haemophilia A and B. FEIBA, Anti-Inhibitor Coagulant Complex, is an activated prothrombin complex concentrate that has been used to treat patients with such complications for almost 30 years. The mechanism of action of FEIBA has been proposed to involve simultaneous FVIII/FIX inhibitor bypassing action in the common, intrinsic and extrinsic coagulation pathways. FEIBA is derived from human plasma that undergoes stringent viral screening followed by significant viral inactivation and removal. To date, there have been no confirmed reports of transmission of hepatitis A, B or C, or of human immunodeficiency viruses associated with the use of the current, vapour-heat-treated FEIBA concentrate. The incidence of thrombotic adverse events recorded in the Baxter pharmacovigilance database for the 10-year postmarket period (1990-99) was approximately 4 : 100,000 infusions of FEIBA. Almost all documented thrombotic events with FEIBA occurred with doses that exceeded dosing recommendations, and known risk factors for cardiovascular disease were evident in more tha...Continue Reading

References

Jul 1, 1992·Journal of Internal Medicine·I M NilssonH Pettersson
Jun 27, 1996·The New England Journal of Medicine·G B SchreiberJ J Korelitz
Oct 26, 1999·Vox Sanguinis·P L TurecekH P Schwarz
Apr 16, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·H J EhrlichE D Gomperts
May 16, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·D Dimichele
Sep 6, 2002·Pathophysiology of Haemostasis and Thrombosis·Christopher A Ludlam
Apr 16, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·M W HilgartnerD M Dimichele

❮ Previous
Next ❯

Citations

Aug 17, 2010·Journal of Thrombosis and Thrombolysis·Richard C Becker
Jan 22, 2009·Advances in Therapy·Chris KnightTessa Kennedy-Martin
Jan 22, 2005·Current Opinion in Pediatrics·Marilyn Manco-Johnson
Feb 5, 2016·Thrombosis and Haemostasis·Maria Fernanda López-FernándezCarmen Sedano Balbas
Jan 12, 2013·Thrombosis and Haemostasis·Gilles CorbonnoisGérard Audibert
Oct 27, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·L M Aledort
Nov 25, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·R MehtaA D Shapiro
Nov 7, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·J Di PaolaC Leissinger
Jul 13, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·D Dimichele, C Négrier
Jan 15, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·V Jimenez-YusteF Hernandez-Navarro
Jan 18, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·L Sieger, L Aledort
Jan 30, 2015·Journal of Thrombosis and Haemostasis : JTH·A-C MartinA Godier
Oct 24, 2008·Anesthesiology·Jerrold H LevyWulf Dietrich
May 16, 2013·The Annals of Pharmacotherapy·Luigi Brunetti, Farooq Bandali
Oct 12, 2017·Blood·Valder R ArrudaBenjamin J Samelson-Jones
Nov 4, 2015·Wiener klinische Wochenschrift·Ingrid PabingerChristoph Male
Dec 25, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Marta A Miyares, Kyle Davis
Nov 3, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·C Escuriola Ettingshausen, W Kreuz
Dec 25, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·William J FaganYancy Chen
Jan 4, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·C NégrierT T Yee
Nov 30, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Oluwaseun OlaiyaShannon L Carpenter
Jul 11, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A SrivastavaUNKNOWN Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia
May 18, 2018·F1000Research·Valder R ArrudaBenjamin J Samelson-Jones
Aug 30, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·J M TeitelN Zourikian
Nov 1, 2012·British Journal of Haematology·David Keeling, Finbarr Cotter
Jul 27, 2018·Research and Practice in Thrombosis and Haemostasis·Joseph R Shaw, Deborah M Siegal
Jul 2, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Kathleen P PrattSébastien Lacroix-Desmazes
Jun 30, 2019·Chest·Parth RaliLisa Moores
Mar 13, 2014·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Xunwei DuanRuian Xu
Aug 10, 2020·Journal of Pediatric Hematology/oncology·Mei Ching GohRajat Bhattacharyya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Haemophilia : the Official Journal of the World Federation of Hemophilia
D M Dimichele, C Negrier
Haemophilia : the Official Journal of the World Federation of Hemophilia
M W HilgartnerD M Dimichele
© 2021 Meta ULC. All rights reserved